United States: On Sale Bar Invalidates Safyral, Beyaz Folate Patent

In Merck & CIE v. Watson Laboratories, Inc., the Federal Circuit found communications between Merck and a potential joint venture partner amounted to a commercial offer to sell that invalidated the Orange Book-listed folate patent at issue. Despite the confidentiality agreement that was in place, a footnote in the court’s opinion indicates that it was an offer for sale to the public. That fact may not matter in the pre-AIA context applicable here, but could be significant for patents governed by the AIA.

The Patent At Issue

The only claim before the court was claim 4 of U.S. Patent No. 6,441,168:

4. A crystalline calcium salt of 5-methyl-(6S)-tetrahydrofolic acid with 2 theta values of 6.5, 13.3, 16.8 and 20.1 (Type I) said crystalline salt having a water of crystallization of at least one equivalent per equivalent of 5-methyltetrahydrofolic acid.

The claim relates to the folate component (“MTHF”) of the combination birth control products sold by Bayer under the trademarks Safyral® and Beyaz®. (There are four other Orange-book listed patents for these products.)

The Invalidating Offer For Sale

The ‘168 patent has a priority date of April 17, 2000, making April 17, 1999 its “critical date” under the pre-AIA version of 35 USC § 102(b). According to the Federal Circuit decision, it was as early as 1997 when Merck began “exploring a strategic partnership [with Weider Nutrition International, Inc.] to introduce dietary supplements with Merck ingredients into the United States.” The Federal Circuit decision highlights the following communications between the parties:

  • “In February 1998, Merck and Weider executed a Confidentiality and Noncompetition Agreement …. Section 5.2 of the Confidentiality Agreement provided: ‘Unless and until such definitive agreement regarding a transaction between Weider and Merck has been signed by both parties, neither party will be under any legal obligation of any kind with respect to such a transaction.'”
  • In August 1998, “Weider notified Merck that it was no longer interested in forming a joint venture …. [but] would like to purchase two kilograms of MTHF on a stand-alone basis.” Weider stated “in order to complete the transaction, it needed information on the price for the product.”
  • “On September 9, 1998 … a manager in Merck's Health, Cosmetic and Nutrition Business Unit, sent Weider a signed fax stating:
    [W]e would like to handle your purchase of [MTHF] very simpl[y]. Therefore please send the order to my attention and I will arrange everything. In addition we need the exact delivery address/person. The price is 25,000 US$ per kg [of MTHF] free delivered to your R&D center in the U.S. Payment terms are 60 days net. With Rick Blair and Richard Bizzaro we discussed a purchase of 2 kg [of MTHF]. If you need more, we have no problem for an immediate[] delivery. After receiving your order you will get the official confirmation of the order.
  • “On September 16, 1998, … Weider's purchasing manager, responded … stating that Weider would order two kilograms of MTHF for delivery to its Salt Lake City, Utah facility,” and requested “the information … needed to complete [the] purchase order, including the ‘[s]pecification sheet for the raw material outlining physical, analytical, and microbial characteristics’ of the MTHF product as well as the ‘material safety data sheets.'” He also “asked for a certificate of insurance naming Weider as an additional insured.”
  • On September 25, 1998, Merck sent the specification and analytical data sheet for the MTHF product, and “informed [Weider] that Weider would receive a certificate of insurance naming it as an additional insured ‘after dispatch of [the] product.'” The communication “reiterated … that the purchase price for the MTHF would be $25,000 per kilogram and that it would be delivered, free of charge, to Weider's Utah facility.”
  • “Merck sent Weider a letter confirming that it had placed a ‘first order’ for two kilograms of MTHF.”

Notwithstanding these communications, the order never was completed. Rather “[o]n January 9, 1999, Weider sent Merck an email noting that the parties had made a ‘mutual decision’ to cancel Weider's "existing order for [MTHF].'”

The District Court Decision

Watson filed Abbreviated New Drug Applications (ANDAs) seeking FDA approval to market generic versions of Safyral® and Beyaz®, in response to which Merck and Bayer brought ANDA litigation in the U.S. District Court for the District of Delaware. Watson stipulated to infringement of claim 4, but challenged its validity on a number of grounds, including the on-sale bar of the pre-AIA version of 35 USC § 102(b).

The District Court rejected Watson’s invalidity arguments, and found that the there had not been a commercial offer for sale because (i) the September 9, 1998 fax “was not sufficiently definite to qualify as a commercial offer because it did not include ‘important safety and liability terms,'” and there was no “definitive agreement” that had been “signed by both parties” as required by the Confidentiality Agreement.

Watson appealed to the Federal Circuit.

The Federal Circuit Decision

The Federal Circuit decision was authored by Judge Mayer and joined by Judges Dyk and Hughes.

Judge Mayer commenced the analysis noting that “[i]nvalidity under the on-sale bar is a question of law based on underlying questions of fact,” and specifically “is a matter of Federal Circuit law, to be analyzed under the law of contracts as generally understood.”

Judge Mayer summarized the principles behind the on-sale bar as follows:

Our patent laws deny a patent to an inventor who applies for a patent more than one year after making an attempt to profit from his invention by putting it on sale. …. Section 102(b)'s on-sale bar is triggered when a claimed invention is: (1) ready for patenting; and (2) the subject of a commercial offer for sale prior to the critical date.

Merck did not challenge the district court’s finding that the invention was “ready for patenting,” so the Federal Circuit focused on whether there had been “a commercial offer for sale.”

Only an offer which rises to the level of a commercial offer for sale, one which the other party could make into a binding contract by simple acceptance (assuming consideration), constitutes an offer for sale under § 102(b).

Considering the communications between Merck and Weider, the Federal Circuit determined that Merck’s September 9, 1998 “detailed fax—providing essential price, delivery, and payment terms—contained all the required elements to qualify as a commercial offer for sale.” The Federal Circuit explained further:

Regardless of whether the communications between Merck and Weider in the fall of 1998 were sufficient to establish a binding contract for the sale of MTHF, they confirm that, at a minimum, both parties understood that Martin's September 9, 1998, fax was an offer to sell the product.

The Federal Circuit disagreed with the district court’s finding that essential terms were missing that prevented the fax from being a complete offer for sale, and also disagreed with the district court’s finding that the terms of Confidentiality Agreement required both parties to sign an offer for sale. The court concluded:

Because Merck's September 9, 1998, offer to sell MTHF was a premature commercial exploitation of its invention, claim 4 of the '168 patent is invalid under the on-sale bar.

Thus, the Federal Circuit reversed the district court’s decision.

Was This A Public Offer For Sale?

In a footnote, the Federal Circuit distinguishes this case from The Medicines Co. v. Hospira, Inc., which is under en banc review:

While this court is currently considering whether an inventor's agreement with another party to manufacture the inventor's product is sufficient to trigger the on-sale bar, see The Medicines Co. v. Hospira, Inc., 805 F.3d 1357, 1358 (Fed. Cir. 2015) (order granting en banc review), there is no dispute that the bar arises when a product is marketed to the public prior to the critical date.

But is an offer for sale made between parties to a confidentiality agreement a “public” offer for sale? The answer to that question may not matter under the pre-AIA version of 35 USC § 102(b) applicable here, but it could make a difference under the AIA’s 35 USC § 102(a)(1), which the USPTO has said does not apply to secret sales.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions